首页|基于网络药理学和实验研究槲皮素治疗阿尔兹海默病的机制

基于网络药理学和实验研究槲皮素治疗阿尔兹海默病的机制

扫码查看
目的 通过网络药理学和实验验证和探究槲皮素(quercetin)治疗阿尔兹海默病(Alzheimer's disease,AD)的作用机制。方法 通过TCMSP、Swiss Target Prediction和Uniprot数据库筛选槲皮素对应的作用靶点。通过TCMIP V2。0、TCMSP、TTD、DrugBank、CTD和DisGeNET数据库得到与AD发病机制相关的靶点,并与槲皮素作用靶点进行映射,将得到的交集靶点作为槲皮素治疗AD的靶点。通过String数据库、CytoNCA和MCODE插件对槲皮素治疗AD的靶点进行各蛋白之间的相互作用研究,作用强的靶点为槲皮素治疗AD的关键靶点。将槲皮素治疗AD的靶点通过Cytoscape3。8。2软件的ClueGO插件和DAVID数据库进行GO和KEGG信号通路富集分析。用蛋白印迹法(Western blotting)和实时荧光定量聚合酶链式反应(real-time fluo-rescence quantitative polymerase chain reaction,qRT-PCR)对预测的通路进行初步验证。结果 筛选出与槲皮素作用的靶点有230个,与442个AD疾病靶点重合的靶点有43个,该靶点涉及多个生物学过程和54条信号通路。通过聚类分析和网络拓扑参数,得到槲皮素治疗AD的6个关键靶点,包括糖原合成酶激酶-3β(glycogen synthase kinase-3 β,GSK3β)、血管内皮生长因子A(vascular endothelial growth factor A,VEGFA)、淀粉样 βA4 蛋白(amyloid βA4 protein,APP)、磷脂酰肌醇 3-激酶调节亚单位α(phosphatidylinositol 3-kinase regulatory subunit α,PIK3R1)、白细胞介素-6(interleukin-6,IL-6)、胰岛素样生长因子 Ⅱ(insulin-like growth factor Ⅱ,IGF2)和转化生长因子β1(transforming growth factor beta-1,TGFβ1);细胞实验结果表明,槲皮素可提高AD细胞模型中的蛋白激酶B(protein kinase B,AKT),GSK-3βmRNA水平,与调控AKT/GSK-3β通路的磷酸化有关。结论 槲皮素可增强损伤神经细胞的稳定性、改善细胞膜的通透性,从而稳定细胞内环境。该作用可能与槲皮素提高AD细胞模型中的AKT、GSK-3β等mRNA水平,调控AKT/GSK-3β通路的磷酸化有关。
Study on the mechanism of quercetin in the treatment of Alzheimer's disease based on network pharmacology and experiment verification
Objective To explore the mechanism of quercetin in the treatment of Alzheimer's disease(AD)through network pharma-cology and experimental verification.Methods The targets of quercetin was screened by TCMSP,Swiss Target Prediction and UniProt database.Then the targets related to the pathogenesis of AD were obtained through TCMIP V2.0,TCMSP,TTD,Drug-Bank,CTD and DiSGeNET databases.Mapped with the target of quercetin,the obtained intersection target was used as the target of quercetin in the treatment of AD.Through String database,CytoNCA and MCODE plug-ins,the protein interaction of quercetin in the treatment of AD was carried out with the strong target as the key target of quercetin in the treatment of AD.The target of quer-cetin for AD treatment was enriched and analyzed by the Clue GO plug-in of Cytoscape 3.8.2 software and the DAVID database for GO and KEGG signaling pathway enrichment.Western blotting and real-time fluorescence quantitative polymerase chain reaction(qRT-PCR)were used to preliminarily verify the predicted pathway.Results 230 quercetin targets were screened,43 of which coin-cided with 442 AD disease targets.The targets involved multiple biological processes and 54 signal pathways.Through cluster analy-sis and network topology parameters,6 key targets of quercetin in the treatment of AD were obtained,including glycogen synthase kinase-3β(GSK3β),vascular endothelial growth factor A(VEGFA),amyloid beta A4 protein(APP),phosphatidylinositol 3-kinase regulatory subunit alpha(PIK3R1),interleukin-6(IL6),insulin-like growth factor Ⅱ(IGF2)and transforming growth factor beta-1(TGFβ1).The results of cell experiment showed that quercetin increased the levels of AKT and GSK-3β mRNA in AD cell model and regulated the phosphorylation of AKT/GSK-3β pathway.Conclusion Quercetin can enhance the stability of injured nerve cells,improve the permeability of cell membrane,and stabilize the intracellular environment.This effect may be related to quercetin increasing the mRNA levels of AKT and GSK-3β in AD cell model and regulating the phosphorylation of AKT/GSK-3β pathway.

quercetinnetwork pharmacologyAlzheimer's diseaseamyloid beta peptide 25-35(Aβ25-35)HT22 cells

巴音桑、吉米丽汗·司马依、艾尼瓦尔·吾买尔、周文婷

展开 >

乌鲁木齐市妇幼保健院,乌鲁木齐 830011

新疆医科大学药学院,乌鲁木齐 830011

槲皮素 网络药理学 阿尔兹海默病 β淀粉样蛋白25-35(Aβ25-35) 小鼠海马神经元细胞

新疆维吾尔自治区自然科学基金国家自然科学基金新疆维吾尔自治区重点学科建设项目(十三五)

2019D01C217816606962016

2024

西北药学杂志
西安交通大学,陕西省药学会

西北药学杂志

CSTPCD
影响因子:0.912
ISSN:1004-2407
年,卷(期):2024.39(2)
  • 20